Newsfeeds - Spark Newswire

1 minute read

JMP Securities Maintains Market Outperform on Ocular Therapeutix, Raises Price Target to $33

Today, 4:22 AM

JMP Securities analyst Jonathan Wolleben maintains Ocular Therapeutix (NASDAQ:OCUL) with a Market Outperform and raises the price target from $30 to $33.

OCUL

9 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For August 10, 2021

By Benzinga Insights

Today, 4:22 AM

ARCT

1 minute read

HC Wainwright & Co. Upgrades Ocular Therapeutix to Buy, Announces $17 Price Target

By Benzinga Newsdesk

Today, 4:22 AM

HC Wainwright & Co. analyst Yi Chen upgrades Ocular Therapeutix (NASDAQ:OCUL) from Neutral to Buy and announces $17 price target.

OCUL

1 minute read

Ocular Therapeutix Q2 EPS $(0.25) Misses $(0.21) Estimate, Sales $11.72M Beat $11.60M Estimate

By Benzinga Newsdesk

Today, 4:22 AM

Ocular Therapeutix (NASDAQ:OCUL) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.21) by 19.05 percent. This is a 60.94 percent increase over losses of $(0.64) per share

OCUL

14 minute read

Earnings Scheduled For August 9, 2021

By Benzinga Insights

Today, 4:22 AM

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.

ACM

7 minute read

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight

By Shanthi Rexaline

Today, 4:22 AM

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.

ABCL

1 minute read

Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases

By Vandana Singh

Today, 4:22 AM

Ocular Therapeutix Inc (NASDAQ:OCUL) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have terminated the option and license agreement collaboration. The termination is effective immediately.…

OCUL

6 minute read

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO

By Shanthi Rexaline

Today, 4:22 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5)

ACAD

2 minute read

Movers

12 Health Care Stocks Moving In Thursday’s After-Market Session

By Benzinga Insights

Today, 4:22 AM

Gainers

ENDP

2 minute read

Ocular Therapeutix Announces Termination Of Collaboration With Regeneron To Develop A Sustained-Release Formulation Of Aflibercept For The Treatment Of Wet AMD And Other Serious Retinal Diseases

By Bill Haddad

Today, 4:22 AM

Ocular plans to Continue its Efforts to Explore Innovative Anti-VEGF Agents BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development,

OCUL